budesonide + formoterol + prednisone

budesonide + formoterol + prednisone refers to a specific therapeutic regimen investigated in a Phase 4 clinical trial (NCT01717703) led by Rafael Stelmach at the University of São Paulo. The protocol was designed to treat difficult-to-control severe asthma using a systematic approach that combines high-dose inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA) with a short course of oral corticosteroids (OCS). Specifically, the regimen utilizes budesonide and formoterol (administered as a maintenance and reliever therapy, or SMART) alongside a two-week induction course of prednisone. Budesonide and prednisone function as glucocorticoid receptor agonists to suppress airway inflammation, while formoterol acts as a selective beta-2 adrenergic receptor agonist to provide prolonged bronchodilation. This multidisciplinary strategy aimed to achieve disease control and characterize clinical, structural, and inflammatory phenotypes in patients who remain symptomatic despite standard care.

Other names

budesonide/formoterol plus prednisoneICS/LABA plus OCS therapybudesonide-Rafael Stelmach-asthma